{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T13:58:42Z","timestamp":1787752722817,"version":"build-2784847793"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T00:00:00Z","timestamp":1725235200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Homozygous or compound heterozygous mutations in JAGN1 cause severe congenital neutropenia. JAGN1-mutant patients present with severe early-onset bacterial infections and most have been described as low-responders to recombinant granulocyte colony-stimulating factor (G-CSF) therapy. In a murine, hematopoietic JAGN1 knockout model, which displays susceptibility to Candida albicans infection in the absence of neutropenia, treatment with granulocyte-macrophage-CSF (GM-CSF) was able to restore the functional defect of neutrophils.<\/jats:p><\/jats:sec><jats:sec><jats:title>Patients<\/jats:title><jats:p>We present two unrelated patients with biallelic JAGN1 mutations, who were both treated with subcutaneous GM-CSF (sargramostim) after treatment failure to G-CSF. The first patient was an 18-year-old pregnant woman who received GM-CSF at 12 weeks of gestation up to a dose of 10 \u00b5g\/kg\/d for 7 days. The second patient was a 5-month-old girl who received GM-CSF for a total of 9 days at a dose of up to 20 \u00b5g\/kg\/d. GM-CSF did not increase neutrophil counts in our patients. Treatment was stopped when neutrophil numbers declined further, no beneficial effect was noticed, and patients presented with infections. No adverse effects were observed in either patient and the fetus. Both patients ultimately underwent successful hematopoietic stem cell transplantation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>Both patients showed a high recurrence rate of severe infections on G-CSF treatment. GM-CSF therapy did not ameliorate the clinical phenotype, in contrast to the improvement of neutrophil function observed in the JAGN1 mouse model. No major additional extra-hematopoietic manifestations were evident in our patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In two unrelated patients, GM-CSF did not have any beneficial effect on neutrophil counts. Patients with JAGN1-mutant SCN with reduced G-CSF responsiveness and elevated infection rate should be evaluated early for stem cell transplantation.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2024.1373495","type":"journal-article","created":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T15:32:27Z","timestamp":1725291147000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Case report: Granulocyte-macrophage colony-stimulating factor sargramostim did not rescue the neutrophil phenotype in two patients with JAGN1-mutant severe congenital neutropenia"],"prefix":"10.3389","volume":"15","author":[{"given":"Susan","family":"Farmand","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne Eva","family":"Aydin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Wustrau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svea","family":"B\u00f6hm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis","family":"Ayuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Escherich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Skokowa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingo","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Lehmberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,9,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1111\/bjh.17135","article-title":"JAGN1 mutations in severe congenital neutropenia","volume":"192","author":"McDermott","year":"2021","journal-title":"Br J Haematol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"17032","DOI":"10.1038\/nrdp.2017.32","article-title":"Severe congenital neutropenias","volume":"3","author":"Skokowa","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1097\/MOP.0b013e32834262f8","article-title":"Genetic etiologies of severe congenital neutropenia","volume":"23","author":"Boztug","year":"2011","journal-title":"Curr Opin Pediatr"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3069","article-title":"JAGN1 deficiency causes aberrant myeloid cell homeostasis and congenital neutropenia","volume":"46","author":"Boztug","year":"2014","journal-title":"Nat Genet"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17137","article-title":"Severe congenital neutropenia-associated JAGN1 mutations unleash a calpain-dependent cell death programme in myeloid cells","volume":"192","author":"Khandagale","year":"2021","journal-title":"Br J Haematol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.24953\/turkjped.2020.02.022","article-title":"A rare case of syndromic severe congenital neutropenia: JAGN1 mutation","volume":"62","author":"Cipe","year":"2020","journal-title":"Turk J Pediatr"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1097\/MPH.0000000000001256","article-title":"Next-generation sequencing reveals A JAGN1 mutation in a syndromic child with intermittent neutropenia","volume":"41","author":"Cifaldi","year":"2019","journal-title":"J Pediatr Hematol Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.03146","article-title":"Comprehensive genetic results for primary immunodeficiency disorders in a highly consanguineous population","volume":"9","author":"Al-Herz","year":"2018","journal-title":"Front Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1136\/jclinpath-2019-206306","article-title":"Screening of genetic variants in ELANE mutation negative congenital neutropenia by next generation sequencing","volume":"73","author":"Arunachalam","year":"2020","journal-title":"J Clin Pathol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.27923","article-title":"Homozygous c.130-131 ins A (pW44X) mutation in the HAX1 gene as the most common cause of congenital neutropenia in Turkey: Report from the Turkish Severe Congenital Neutropenia Registry","volume":"66","author":"Yilmaz Karapinar","year":"2019","journal-title":"Pediatr Blood Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-015-0156-2","article-title":"JAGN1 deficient severe congenital neutropenia: two cases from the same family","volume":"35","author":"Baris","year":"2015","journal-title":"J Clin Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V75.5.1056.1056","article-title":"Differential effects of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor in children with severe congenital neutropenia","volume":"75","author":"Welte","year":"1990","journal-title":"Blood"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3070","article-title":"Jagunal homolog 1 is a critical regulator of neutrophil function in fungal host defense","volume":"46","author":"Wirnsberger","year":"2014","journal-title":"Nat Genet"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-111-11-887","article-title":"The effect of recombinant human granulocyte-macrophage colony-stimulating factor on neutropenia and related morbidity in chronic severe neutropenia","volume":"111","author":"Ganser","year":"1989","journal-title":"Ann Intern Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V81.10.2496.2496","article-title":"A randomized controlled phase III trial of recombinant human granulocyte colony-stimulating factor (filgrastim) for treatment of severe chronic neutropenia","volume":"81","author":"Dale","year":"1993","journal-title":"Blood"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2021.746159","article-title":"Efficacy of low-dose rhGM-CSF treatment in a patient with severe congenital neutropenia due to CSF3R deficiency: case report of a novel biallelic CSF3R mutation and literature review","volume":"9","author":"Zhou","year":"2021","journal-title":"Front Pediatr"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-07-661264","article-title":"GM-CSF stimulates granulopoiesis in a congenital neutropenia patient with loss-of-function biallelic heterozygous CSF3R mutations","volume":"126","author":"Klimiankou","year":"2015","journal-title":"Blood"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-11-535419","article-title":"Inherited biallelic CSF3R mutations in severe congenital neutropenia","volume":"123","author":"Triot","year":"2014","journal-title":"Blood"},{"key":"B19","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1097\/MOH.0b013e32834da96e","article-title":"Hematopoietic stem cell transplantation for severe congenital neutropenia","volume":"19","author":"Connelly","year":"2012","journal-title":"Curr Opin Hematol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1097\/MOH.0b013e328303b9f6","article-title":"G-CSF receptor mutations in patients with congenital neutropenia","volume":"15","author":"Germeshausen","year":"2008","journal-title":"Curr Opin Hematol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2010.08216.x","article-title":"Stable long-term risk of leukaemia in patients with severe congenital neutropenia maintained on G-CSF therapy","volume":"150","author":"Rosenberg","year":"2010","journal-title":"Br J Haematol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1097\/MOH.0b013e32831952de","article-title":"Genetic and molecular diagnosis of severe congenital neutropenia","volume":"16","author":"Ward","year":"2009","journal-title":"Curr Opin Hematol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-04-149575","article-title":"Granulocyte colony-stimulating factor delays neutrophil apoptosis by inhibition of calpains upstream of caspase-3","volume":"112","author":"van Raam","year":"2008","journal-title":"Blood"},{"key":"B24","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1186\/s13023-014-0183-8","article-title":"Clinical spectrum and long-term follow-up of 14 cases with G6PC3 mutations from the French Severe Congenital Neutropenia Registry","volume":"9","author":"Desplantes","year":"2014","journal-title":"Orphanet J Rare Dis"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1097\/MPH.0000000000001258","article-title":"Congenital neutropenia patient with hypomorphic biallelic CSF3R mutation responding to GCSF","volume":"41","author":"Yilmaz Karapinar","year":"2019","journal-title":"J Pediatr Hematol Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1111\/nyas.13097","article-title":"Role of CSF3R mutations in the pathomechanism of congenital neutropenia and secondary acute myeloid leukemia","volume":"1370","author":"Klimiankou","year":"2016","journal-title":"Ann N Y Acad Sci"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1097\/MPH.0000000000001359","article-title":"Management of a patient with congenital biallelic CSF3R mutation with GM-CSF","volume":"42","author":"Yilmaz Karapinar","year":"2020","journal-title":"J Pediatr Hematol Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1500861","article-title":"G-CSF and GM-CSF in neutropenia","volume":"195","author":"Mehta","year":"2015","journal-title":"J Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/nm.1913","article-title":"NAMPT is essential for the G-CSF-induced myeloid differentiation via a NAD(+)-sirtuin-1-dependent pathway","volume":"15","author":"Skokowa","year":"2009","journal-title":"Nat Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-016-2894-5","article-title":"GM-CSF treatment is not effective in congenital neutropenia patients due to its inability to activate NAMPT signaling","volume":"96","author":"Koch","year":"2017","journal-title":"Ann Hematol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1002\/JLB.4A0118-030RR","article-title":"JAGN1 is required for fungal killing in neutrophil extracellular traps: Implications for severe congenital neutropenia","volume":"104","author":"Khandagale","year":"2018","journal-title":"J Leukoc Biol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20200559","article-title":"A crucial role for Jagunal homolog 1 in humoral immunity and antibody glycosylation in mice and humans","volume":"218","author":"Hagelkruys","year":"2021","journal-title":"J Exp Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2023.1223191","article-title":"Severe congenital neutropenia due to jagunal homolog 1 (JAGN1) mutation: a case report and literature review","volume":"11","author":"Thomas","year":"2023","journal-title":"Front Pediatr"},{"key":"B34","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1186\/s12887-023-04024-y","article-title":"JAGN1 mutation with distinct clinical features; two case reports and literature review","volume":"23","author":"Hojabri","year":"2023","journal-title":"BMC Pediatr"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1373495\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T15:32:35Z","timestamp":1725291155000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1373495\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,2]]},"references-count":34,"alternative-id":["10.3389\/fimmu.2024.1373495"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1373495","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,2]]},"article-number":"1373495"}}